Multi-dose oral abuse deterrent formulation of Loperamide using Hot melt extrusion

Publication date: Available online 16 August 2019Source: International Journal of PharmaceuticsAuthor(s): Pavan Kumar Nukala, Siddhant Palekar, Manali Patki, Yige Fu, Ketan PatelAbstractLoperamide, an over the counter anti-diarrheal drug, also infamously referred to as “poor man's methadone”. Due to the ease of availability and low price, people/patients abuse it by consuming more than 30 tablets to achieve euphoric effect and to combat opioid withdrawal. But supratherapeutic doses of loperamide result in severe respiratory depression, cardiac dysrhythmia and mortality. To address this issue, we developed a unique and innovative technology to deter multi-dose oral abuse. The concept is to design a tablet which can immediate release loperamide in diarrheic patients (single tablet) while stops loperamide release in case of intentional multi-dose ingestion. Loperamide was molecularly dispersed into gastric soluble cationic polymers - Eudragit® EPO and Kollicoat® Smartseal 100P using hot melt extrusion to obtain filament. Filaments were milled and compressed into tablets ((Eudragit®EPO (SJU1) and Kollicoat® Smartseal (SJU2)) with optimized amount of L-Arginine. Dissolution in 250 mL of Fasted state simulated gastric fluid (FaSSGF) revealed that single tablet of Imodium® (marketed formulation) and SJU1 showed>85% of release within 15 minutes. Most importantly, in multi-unit dissolution (15 tablets), Imodium® exhibited>90% release...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research

Related Links:

We describe a case of a 49-year-old, male, Caucasian, pharmaco-resistant patient with a recurrent major depressive disorder, who developed acute pulmonary embolism during a course of inpatient right-unilateral ultra-brief electroconvulsive therapy. After the stabilization of his somatic condition, we were able to safely continue with further ECT applications until his mood normalized and he was able to return to his normal life outside the hospital. Case reports on this topic are scarce – our article demonstrates that electroconvulsive treatment, with proper precautionary measures (anti-aggregative or anti-coagulatio...
Source: Brain Stimulation - Category: Neurology Source Type: research
Source: BMJ Comments - Category: General Medicine Source Type: forums
Source: BMJ Comments - Category: General Medicine Source Type: forums
Source: BMJ News - Category: General Medicine Source Type: research
New research shows the antidepressant Sertraline may help alleviate anxiety even better than they reduce symptoms of depression.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news
Authors: Malik E, Adelson M, Sason A, Schreiber S, Peles E Abstract Objective: Comorbidity of depression among individuals with opioid addiction is highly prevalent, but their outcome in methadone maintenance treatment (MMT) is not well determined. Methods: Characteristics and outcomes (retention until December 2017) of newly admitted and already (5.5 ± 4 years) in MMT patients with available Hamilton Depression Rating Scale (HAM-D) scores on admission were studied. Results: During psychiatric intake on admission, 70 (21.2%) of 330 patients were diagnosed with high depressive symptoms beyond th...
Source: Journal of Dual Diagnosis - Category: Addiction Tags: J Dual Diagn Source Type: research
Publication date: Available online 19 September 2019Source: The Lancet PsychiatryAuthor(s): Gemma Lewis, Larisa Duffy, Anthony Ades, Rebekah Amos, Ricardo Araya, Sally Brabyn, Katherine S Button, Rachel Churchill, Catherine Derrick, Christopher Dowrick, Simon Gilbody, Christopher Fawsitt, William Hollingworth, Vivien Jones, Tony Kendrick, David Kessler, Daphne Kounali, Naila Khan, Paul Lanham, Jodi PervinSummaryBackgroundDepression is usually managed in primary care, but most antidepressant trials are of patients from secondary care mental health services, with eligibility criteria based on diagnosis and severity of depres...
Source: The Lancet Psychiatry - Category: Psychiatry Source Type: research
We report a case of an individual referred for cognitive training in view of persisting cognitive and functional difficulties despite clinical improvement. The intervention consisted of therapist-guided sessions along with homework practice. A smartphone application was developed for cognitive stimulation, and used with other techniques for cognitive stimulation, strategy use, and generalization to achieve transfer of effects. Following 12 weeks of intervention, changes were observed on executive functions including verbal fluency and planning, and smaller changes across measures of attention and working memory. Notably, t...
Source: Journal of Obsessive Compulsive and Related Disorders - Category: Psychiatry Source Type: research
ConclusionsOverall, our findings suggest that co-occurring symptoms (e.g., anxiety, depression) may be worthwhile targets to examine in future research aimed to extend our understanding of the mechanisms through which chronic sleep deprivation exerts deleterious effects on OCS. Extending findings to clinical populations and treatment contexts may have important implications for our understanding of the links between insomnia and OCS.
Source: Journal of Obsessive Compulsive and Related Disorders - Category: Psychiatry Source Type: research
Women with postpartum depression may experience significant reductions in symptoms after just 3 days of taking a novel neuroactive steroid, new research suggests.Medscape Medical News
Source: Medscape Psychiatry Headlines - Category: Psychiatry Tags: Psychiatry News Source Type: news
More News: Depression | Drugs & Pharmacology | Gastroenterology | Imodium | Loperamide | Respiratory Medicine | Substance Abuse